Pfizer To Work On Chinese Medicines
Pfizer and the Institute of Basic Theory at the China Academy of Traditional Chinese Medicine have signed a three-year agreement to study traditional Chinese herbs as a source of potential new medicines.
Under the agreement, the Institute will collect, identify and archive plants which have been used in traditional Chinese medicine, and provide extracts which Pfizer will screen for activity against various disease targets. The Institute will receive a royalty on sales if an agent from this effort reaches the marketplace.
In addition, Pfizer will analyse the relative frequency of biological activity that will be observed during the screening of extracts from both traditional Chinese plants and randomly collected US plants. The company will share this information with the Institute.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze